Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
oleh: Nitesh D. Kuhadiya, Israa Mahmood
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-04-01 |
Deskripsi
Abstract Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m2)